Furthermore, GLP-1 plays a protective role in cardiac microvasculature in diabetes by preventing apoptosis, oxidative stress, and microvascular dysfunction. GLP-1 is thought to mediate this through inhibiting Rho GTPase in the cyclic adenosine 3′,5′-monophosphate (cAMP)/protein kinase A (PKA) ...
As previously noted, DPP-4 rapidly cleaves and inactivates GLP-1, resulting in its very short half-life (2–3 min). While DPP-4 expression is significantly increased in patients with obesity and T2DM, the incretin effect is markedly impaired. Early studies revealed that GLP-1 injections impro...
Researchers concluded that GLP-1 drugs might be beneficial as a primary prevention tool for CVD in clinically silent patients. According to the whitepaper, after three years of taking a GLP-1 drug, patients had a major adverse cardiac event (MACE) risk score that was 15%-20%...
Both DPP4 inhibitors and GLP-1 analogue are being developed as a novel class of oral antihyperglycemic agent in the treatment of diabetes. However, the benefits of both agents on the cardiovascular function of endotoxemic animals remains poorly understood. In this study, the cardiac function of ...
Exploratory endpoints will include the effect of DA-1726 on metabolic parameters, cardiac parameters, fasting lipid levels, body weight, waist circumference and body mass index (BMI), among others. About DA-1726 DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual ...
C/C homozygotes, who had been found to derive cardiovascular benefits from intensive treatment, showed a 22% increase in GLP-1 levels during follow-up. By contrast, T/T homozygotes, who had been found to experience increased cardiac mortality with intensive treatment, showed a 28% reduction ...
DISCUSSION This information describes pleiotropic effects of glucagon-like peptide 1 (GLP-1) with focus on effects on cardiac and renal function DISCUSSION Insulin resistance is present in the setting of congestive heart failure. Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin ...
GLP-1RA (such as exendin-4) treatment can reduce the size of MI impacted cardiac volume in rats, inhibit ventricular dilation, myocardial fibrosis and hypertrophy in vivo [72]. Mechanically, GLP-1RAs regulate insulin-like growth factor-1/2 and upregulate α-estrogen receptors to exert ...
to identify in PubMed the complimentary ways of action leading to clinical benefit (in lowering HbA1c, body weight, renal, and cardiac risk factors and events) of the combination of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA). ...
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors. Cardiovasc Diabetol. 2023;22(1):24. Article PubMed PubMed Central CAS Google Scholar Balestrieri ML, Rizzo MR, Barbieri M, Paolisso P, D'Onofrio N, Giovane A, Siniscalchi M...